Article ; Online: Salvage Intra-arterial Chemotherapy for Recurrent or Persistent Intraocular Retinoblastoma: A Study of 24 Eyes.
Ophthalmology. Retina
2022 Volume 7, Issue 3, Page(s) 275–281
Abstract: Objective: To analyze the outcomes of salvage intra-arterial chemotherapy (IAC) for recurrent or persistent intraocular retinoblastoma after failure with other treatment modalities.: Design: Retrospective study.: Subjects: Twenty-four eyes of 23 ... ...
| Abstract | Objective: To analyze the outcomes of salvage intra-arterial chemotherapy (IAC) for recurrent or persistent intraocular retinoblastoma after failure with other treatment modalities. Design: Retrospective study. Subjects: Twenty-four eyes of 23 patients. Intervention: Intra-arterial chemotherapy. Main outcome measures: Globe salvage, metastasis, and death. Results: The mean age at the time of salvage IAC was 41 months (median, 36 months; range, 14-86 months). All patients (n = 23) received IV chemotherapy (IVC) as the primary treatment. The mean number of IVC cycles before salvage IAC was 10 (median, 12; range, 6-18). The indications for salvage IAC were tumor recurrence (n = 17; 71%) or persistent tumor (n = 7; 29%) post-IVC. The mean number of salvage IAC cycles was 3 (median, 3; range, 1-6). Of 24 eyes, 17 eyes (71%) achieved tumor regression with salvage IAC, whereas 7 (29%) eyes displayed poor response. Of these 17 eyes with initial tumor regression, 9 (38%) eyes sustained good response, whereas 8 (33%) eyes displayed tumor recurrence over a mean follow-up period of 21 months (median, 21 months; range, 6-44 months). The mean interval between IAC and tumor recurrence (n = 8) was 4 months (median, 3 months; range, 1-14 months). Of these 8 eyes, globe salvage was achieved in 5 (21%) eyes with additional alternate treatment. Of the 7 eyes with poor response to IAC, globe salvage was achieved in 1 (4%) eye with additional alternate treatment. Overall, globe salvage was achieved in 15 (63%) eyes. Conclusions: Salvage IAC is an effective treatment for recurrent and persistent retinoblastoma, enabling globe salvage in 63% cases. Financial disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. |
|---|---|
| MeSH term(s) | Humans ; Child, Preschool ; Retinoblastoma/drug therapy ; Retinal Neoplasms/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Retrospective Studies ; Melphalan ; Infusions, Intra-Arterial |
| Chemical Substances | Melphalan (Q41OR9510P) |
| Language | English |
| Publishing date | 2022-10-03 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ISSN | 2468-6530 |
| ISSN (online) | 2468-6530 |
| DOI | 10.1016/j.oret.2022.09.006 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.
Inter-library loan at ZB MED
Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.